Join Growin Stock Community!

Inflarx n.v.IFRX.US Overview

US StockHealthcare
(No presentation for IFRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IFRX AI Insights

IFRX Overall Performance

IFRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IFRX Recent Performance

-1.95%

Inflarx n.v.

0.05%

Avg of Sector

-0.31%

S&P500

IFRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IFRX Key Information

IFRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IFRX Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Price of IFRX

IFRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IFRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
991.86
PB Ratio
1.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-8223.06%
Net Margin
-63818.90%
Revenue Growth (YoY)
-62.71%
Profit Growth (YoY)
-754.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
991.86
PB Ratio
1.19
Price-to-FCF
-
Gross Margin
-8223.06%
Net Margin
-63818.90%
Revenue Growth (YoY)
-62.71%
Profit Growth (YoY)
-754.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IFRX's latest earnings report released?

    The most recent financial report for Inflarx n.v. (IFRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IFRX's short-term business performance and financial health. For the latest updates on IFRX's earnings releases, visit this page regularly.

  • What is the operating profit of IFRX?

    According to the latest financial report, Inflarx n.v. (IFRX) reported an Operating Profit of -9.48M with an Operating Margin of -39,769.22% this period, representing a growth of 38.3% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IFRX's revenue growth?

    In the latest financial report, Inflarx n.v. (IFRX) announced revenue of 23.83K, with a Year-Over-Year growth rate of -80.75%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does IFRX have?

    As of the end of the reporting period, Inflarx n.v. (IFRX) had total debt of 970.86K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IFRX have?

    At the end of the period, Inflarx n.v. (IFRX) held Total Cash and Cash Equivalents of 6.45M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IFRX go with three margins increasing?

    In the latest report, Inflarx n.v. (IFRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 98.6%%, operating margin of -39,769.22%%, and net margin of -51,452.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IFRX's profit trajectory and future growth potential.

  • Is IFRX's EPS continuing to grow?

    According to the past four quarterly reports, Inflarx n.v. (IFRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IFRX?

    Inflarx n.v. (IFRX)'s Free Cash Flow (FCF) for the period is -9.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 5.52% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.